Myomo Inc ( (MYO) ) has released its Q2 earnings. Here is a breakdown of the information Myomo Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Myomo, Inc. is a wearable medical robotics company specializing in devices that enhance arm and hand function for individuals with neurological disorders and upper-limb paralysis. The company is known for its MyoPro product line, which is unique in its ability to restore arm function using non-invasive sensors to detect EMG signals.
In its second quarter of 2025, Myomo reported a revenue increase of 28% to $9.7 million, with significant contributions from Medicare Part B patients. Despite this growth, the company faced challenges with lead quality and pipeline conversion, prompting strategic shifts in advertising and engagement with healthcare professionals.
Key financial metrics revealed a gross margin decline to 62.7% due to increased material and overhead costs, while operating expenses surged by 65% driven by higher payroll and advertising costs. The company also reported an operating loss of $4.6 million, reflecting increased investments in growth and development.
Looking ahead, Myomo has adjusted its 2025 revenue guidance to a range of $40 million to $42 million, reflecting a more conservative outlook compared to previous expectations. The company remains focused on improving lead quality and expanding its network of healthcare providers to drive future growth.